Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 2
2013 3
2014 2
2015 1
2016 2
2017 1
2018 3
2019 1
2020 3
2021 3
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Results by year
Filters applied: . Clear all
Page 1
Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol.
Sablerolles RSG, Goorhuis A, GeurtsvanKessel CH, de Vries RD, Huckriede ALW, Koopmans MPG, Lafeber M, Postma DF, van Baarle D, Visser LG, Dalm VASH, Kootstra NA, Rietdijk WJR, van der Kuy PHM. Sablerolles RSG, et al. Among authors: lafeber m. Front Immunol. 2021 Sep 24;12:753319. doi: 10.3389/fimmu.2021.753319. eCollection 2021. Front Immunol. 2021. PMID: 34691071 Free PMC article. No abstract available.
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Geers D, Schmitz KS, Garcia Garrido HM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Lafeber M, van Baarle D, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH Research Group. Sablerolles RSG, et al. Among authors: lafeber m. N Engl J Med. 2022 Mar 10;386(10):951-963. doi: 10.1056/NEJMoa2116747. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045226 Free PMC article. Clinical Trial.
The cardiovascular polypill in high-risk patients.
Lafeber M, Spiering W, Singh K, Guggilla RK, Patil V, Webster R; SPACE collaboration. Lafeber M, et al. Eur J Prev Cardiol. 2012 Dec;19(6):1234-42. doi: 10.1177/1741826711428066. Epub 2011 Oct 21. Eur J Prev Cardiol. 2012. PMID: 22019908 Review.
Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad?
Versmissen J, Verdonk K, Lafeber M, van den Akker JPC, Hunfeld NGM, Hoorn EJ, Danser AHJ. Versmissen J, et al. Among authors: lafeber m. J Hypertens. 2020 Jun;38(6):1196-1197. doi: 10.1097/HJH.0000000000002472. J Hypertens. 2020. PMID: 32371817 Free PMC article. No abstract available.
COvid MEdicaTion (COMET) study: protocol for a cohort study.
Sablerolles RSG, Hogenhuis FEF, Lafeber M, van de Loo BPA, Borgsteede SD, Boersma E, Versmissen J, van der Kuy HM; COMET Research team. Sablerolles RSG, et al. Among authors: lafeber m. Eur J Hosp Pharm. 2020 Jul;27(4):191-193. doi: 10.1136/ejhpharm-2020-002329. Eur J Hosp Pharm. 2020. PMID: 32587077 Free PMC article.
Durability of immune responses after boosting in Ad26.COV2.S-primed healthcare workers.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Schmitz KS, Geers D, Bogers S, van Haren E, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Akkerman R, Beukema M, Lafeber M, van Baarle D, de Vries RD, van der Kuy PHM, GeurtsvanKessel CH. Sablerolles RSG, et al. Among authors: lafeber m. Clin Infect Dis. 2022 Jun 20:ciac495. doi: 10.1093/cid/ciac495. Online ahead of print. Clin Infect Dis. 2022. PMID: 35723273 Free PMC article.
[Cardiovascular polypill in high risk patients].
Lafeber M, Spiering W, Bots ML, de Valk V, Visseren FL, Grobbee DE. Lafeber M, et al. Ned Tijdschr Geneeskd. 2011;155(44):A3070. Ned Tijdschr Geneeskd. 2011. PMID: 22067559 Review. Dutch.
23 results